Citius Pharmaceuticals target adjusted to $4 for split at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Citius Pharmaceuticals (CTXR) to $4 from $100 and keeps a Buy rating on the shares following the one-for-25 reverse stock split. Citius has potential to have two therapies, Mino-Lok and Lymphir, in commercialization by first half 2026, which is underappreciated at current share levels, the analyst tells investors in a research note.